13F reference period
Q2 2026
Security Snapshot
Metagenomi Therapeutics, Inc. - Common stock, par value $0.0001 per share (MGX) Institutional Ownership
CUSIP: 59102M104
13F Institutional Holders and Ownership History from Q1 2024 to Q3 2026
Institutions Reporting
43
Shares (Excl. Options)
6.26M
Full value: 6,262,702 · shares · 30 Jun 2026Price
$1.19
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock, par value $0.0001 per share
- Symbol
- MGX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 6,262,702
- Total 13F value
- $7,452,822
- Portfolio coverage rank
- 0%
- Share change
- -200,885
- Value change
- -$249,510
- Number of holders
- 43
- Shares outstanding
- 37,837,562
- SEC-reported price per share
- $1.06
- Insider filing price
- $1.06
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- MGX - Metagenomi Therapeutics, Inc. - Common stock, par value $0.0001 per share is tracked under CUSIP 59102M104.
- 43 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 47 to 43 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$8.65M
Full value: $8,651,563 · USD · 31 Mar 2026.$7.45M
Full value: $7,452,822 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 43 institutions filings for Q2 2026.
Security key
59102M104
13F reference period
Q2 2026
13F holders
43
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
MGX full holder history
Metagenomi Therapeutics, Inc. SEC filings
Metagenomi Therapeutics, Inc. company facts
Metagenomi Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 59102M104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
MGX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Thomas Brian C. | 7.3% | $3,369,813 | 2,762,142 | Thomas Brian C. | 30 Jun 2026 |
As of 30 Jun 2026,
43
institutional investors reported holding
shares of
Metagenomi Therapeutics, Inc. - Common stock, par value $0.0001 per share (MGX).
This represents
17%
of the company’s total
outstanding shares.
6.26M
Full value: 6,262,702 · shares · 30 Jun 202637.84M
Full value: 37,837,562 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
16%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 1,077,700 | +1.9% | 0% | $1,282,463 |
| RENAISSANCE TECHNOLOGIES LLC | 2% | 742,400 | -5.8% | 0% | $883,456 |
| Catalio Capital Management, LP | 1.4% | 528,993 | 0% | 0.12% | $629,502 |
| Peapod Lane Capital LLC | 1.4% | 525,024 | +1.6% | 0.42% | $624,779 |
| TWO SIGMA INVESTMENTS, LP | 1.4% | 513,701 | +3.4% | 0% | $611,304 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.1% | 400,300 | +1.1% | 0.01% | $476,357 |
| WELLS FARGO & COMPANY/MN | 1% | 379,508 | +88% | 0% | $451,614 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.76% | 288,665 | -19% | 0% | $343,672 |
| PURA VIDA INVESTMENTS, LLC | 0.7% | 264,391 | 0% | 0.85% | $314,625 |
| BlackRock, Inc. | 0.68% | 257,631 | +12% | 0% | $306,581 |
| VANGUARD FIDUCIARY TRUST CO | 0.45% | 171,251 | +0.63% | 0% | $203,789 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.42% | 160,000 | -58% | 0% | $190,400 |
| STATE STREET CORP | 0.32% | 119,850 | -0.48% | 0% | $142,622 |
| MILLENNIUM MANAGEMENT LLC | 0.3% | 114,025 | -33% | 0% | $135,690 |
| Man Group plc | 0.29% | 109,130 | +39% | 0% | $129,865 |
| Resolute Advisors LLC | 0.24% | 89,944 | 0% | 0.03% | $107,033 |
| Marquette Asset Management, LLC | 0.19% | 72,121 | 0.01% | $85,824 | |
| NORTHERN TRUST CORP | 0.18% | 68,938 | -8.3% | 0% | $82,036 |
| RBF Capital, LLC | 0.17% | 64,021 | 0% | 0% | $76,185 |
| XTX Topco Ltd | 0.15% | 55,707 | +37% | 0% | $66,291 |
| BBR PARTNERS, LLC | 0.14% | 53,403 | 0% | 0% | $63,550 |
| JANE STREET GROUP, LLC | 0.1% | 38,396 | -75% | 0% | $45,691 |
| Fortitude Advisory Group L.L.C. | 0.1% | 37,190 | 0% | 0.02% | $44,256 |
| CITADEL ADVISORS LLC | 0.05% | 17,851 | +5% | 0% | $21,243 |
| Qube Research & Technologies Ltd | 0.04% | 16,850 | 0% | $20,052 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Headline period
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 528,282 | $559,979 | -$121,792 | $1.06 | 2 |
| 2026 Q2 | 6,262,702 | $7,452,822 | -$249,510 | $1.19 | 43 |
| 2026 Q1 | 6,463,712 | $8,651,563 | -$474,616 | $1.34 | 47 |
| 2025 Q4 | 6,764,212 | $10,956,656 | +$2,099,977 | $1.62 | 54 |
| 2025 Q3 | 6,000,175 | $14,170,933 | -$1,224,304 | $2.37 | 57 |
| 2025 Q2 | 6,750,362 | $9,989,847 | -$3,542,499 | $1.48 | 67 |
| 2025 Q1 | 9,515,509 | $13,160,529 | -$3,437,465 | $1.36 | 76 |
| 2024 Q4 | 10,727,379 | $38,723,693 | +$750,752 | $3.61 | 76 |
| 2024 Q3 | 11,662,818 | $25,306,458 | -$3,651,260 | $2.17 | 65 |
| 2024 Q2 | 12,188,453 | $49,568,061 | -$9,507,864 | $4.08 | 54 |
| 2024 Q1 | 13,335,479 | $140,258,517 | +$140,258,517 | $10.55 | 49 |